Business Building

Many claim that investing in clinical studies is unnecessary because cannabis often lacks protectable intellectual property (IP), studies are very expensive, and success remains uncertain. But now, a German company is proving the opposite! Germany, the land of inventors and thinkers, is once again at the forefront of innovation. Particularly in southern Germany, where hidden […]

Barcelona is one of the world’s most well-known hotspots for cannabis tourism and home to hundreds of cannabis social clubs. These days, the international cannabis community gathers here, especially during ICBC and Spannabis, the world’s largest cannabis trade fair. While the latest trends, technologies, and business models are discussed at the conference during the day,

The era of unregulated online advertising for medical cannabis seems to be over. With a preliminary injunction, the Hamburg Regional Court (LG) has put the DrAnsay platform and its operator, Can Ansay, in check. The North Rhine Chamber of Pharmacists (AKNR) filed a lawsuit – and won. This marks the beginning of a new phase

On February 27, 2025, two significant rulings were handed down that impact the pharmacy market and digital platform models in Germany. The European Court of Justice (ECJ) and the Federal Court of Justice (BGH) issued key decisions that could also be relevant for cannabis startups. Below, we take a look at these rulings and analyze

The medical cannabis market in Germany is evolving rapidly, and digital transformation is playing a crucial role in shaping its future. As more patients gain access to cannabis treatments, the importance of innovative platforms and technologies, particularly apps, continues to grow. Startups and investors in the cannabis sector have a unique opportunity to capitalize on

The German healthcare landscape is on the brink of transformation, with telemedicine emerging as a critical tool in bridging gaps in patient care. This is particularly true for cannabis-based treatments, where regulatory hurdles, limited data, and stigma have traditionally constrained both access and innovation. As the German government revisits its policies on cannabis and digital

Opportunites and regulation in the cannabis industry are going hand in hand. A recent ruling by the Administrative Court of Düsseldorf has clarified that Dronabinol solutions provided in pre-prepared sets, like those from Caelo, cannot be classified as compounded medications. Instead, the court determined these products are finished medicinal products, requiring full regulatory approval under

New markets can only raise, when regulation changes. Thats what happened this month in a court in Düsseldorf, Germany. Its all about the question: How many work steps must be added in the pharmacy so that dronabinol can still be dispensed as a magistral preparation? According to the Düsseldorf Administrative Court (VG), testing, filling, bottling

As market uncertainty looms and valuations drop to all-time lows, the current climate offers a golden opportunity for strategic acquisitions. With elections and policy shifts on the horizon in Germany, acting decisively now could position businesses to thrive in a post-election economy. Also asking in the end of the article, if the momentum in Canada

The legalization of cannabis in Germany was meant to mark a turning point, opening the doors to a regulated and thriving market. Instead, it has unveiled a labyrinth of legal ambiguities, particularly around cannabis clones and cuttings. These essential building blocks of the industry are caught in a tangle of inconsistent interpretations, unclear definitions, and